Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Infectious Diseases |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702014000100048 |
Resumo: | Background:Tolerance and response to antiviral HCV treatment is poor in advanced fibrosis. The aim of this study was to assess SVR rate and its predictive factors in HCV advanced fibrosis patients treated in real life with full dose PEG-IFN plus RBV and to evaluate the adverse events related to treatment.Methods:A multicentric, retrospective study was conducted at six university hospitals. METAVIR F3 and F4 HCV monoinfected patients who were treated with PEG-IFN and RBV had their data analyzed. A stepwise logistic regression analysis was performed to identify the variables independently related to SVR. Adverse events were recorded during treatment.Results:308 patients were included, 75% genotype 1 and 23% genotype 3. METAVIR F3 was present in 39% and F4 in 61% of patients. The median Child Pugh score for F4 patients was 5 (5–9). The global SVR rate was 34%, 11% were relapsers and 55% were nonresponders. SVR rates were similar between patients treated with PEG-IFN alfa 2a or alfa 2b (p = 0.24). SVR rates according to Child–Pugh score were 26% (Child A) and 18% (Child B). The independent factors related to SVR in F4 patients were genotype 3, RVR and fewer Child Pugh score points. Treatment interruption occurred in 31% patients and death occurred in 1.9%, all with liver cirrhosis.Conclusion:Treatment of HCV in patients with advanced fibrosis should not be postponed. However, a very careful evaluation of cirrhotic patients must be performed before treatment is indicated and careful monitoring is required during treatment. |
id |
BSID-1_2701891050e2742dfc9a681f39ffe7b4 |
---|---|
oai_identifier_str |
oai:scielo:S1413-86702014000100048 |
network_acronym_str |
BSID-1 |
network_name_str |
Brazilian Journal of Infectious Diseases |
repository_id_str |
|
spelling |
Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life studyHepatitis CAdvanced fibrosisPeginterferonRibavirinBackground:Tolerance and response to antiviral HCV treatment is poor in advanced fibrosis. The aim of this study was to assess SVR rate and its predictive factors in HCV advanced fibrosis patients treated in real life with full dose PEG-IFN plus RBV and to evaluate the adverse events related to treatment.Methods:A multicentric, retrospective study was conducted at six university hospitals. METAVIR F3 and F4 HCV monoinfected patients who were treated with PEG-IFN and RBV had their data analyzed. A stepwise logistic regression analysis was performed to identify the variables independently related to SVR. Adverse events were recorded during treatment.Results:308 patients were included, 75% genotype 1 and 23% genotype 3. METAVIR F3 was present in 39% and F4 in 61% of patients. The median Child Pugh score for F4 patients was 5 (5–9). The global SVR rate was 34%, 11% were relapsers and 55% were nonresponders. SVR rates were similar between patients treated with PEG-IFN alfa 2a or alfa 2b (p = 0.24). SVR rates according to Child–Pugh score were 26% (Child A) and 18% (Child B). The independent factors related to SVR in F4 patients were genotype 3, RVR and fewer Child Pugh score points. Treatment interruption occurred in 31% patients and death occurred in 1.9%, all with liver cirrhosis.Conclusion:Treatment of HCV in patients with advanced fibrosis should not be postponed. However, a very careful evaluation of cirrhotic patients must be performed before treatment is indicated and careful monitoring is required during treatment.Brazilian Society of Infectious Diseases2014-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702014000100048Brazilian Journal of Infectious Diseases v.18 n.1 2014reponame:Brazilian Journal of Infectious Diseasesinstname:Brazilian Society of Infectious Diseases (BSID)instacron:BSID10.1016/j.bjid.2013.05.007info:eu-repo/semantics/openAccessSilva,Giovanni FariaVillela-Nogueira,Cristiane A.Brandão Mello,Carlos EduardoSoares,Elza CotrimCoelho,Henrique Sergio M.Abrão Ferreira,Paulo RobertoRuiz,Fernando José Goeseng2015-08-28T00:00:00Zoai:scielo:S1413-86702014000100048Revistahttps://www.bjid.org.br/https://old.scielo.br/oai/scielo-oai.phpbjid@bjid.org.br||lgoldani@ufrgs.br1678-43911413-8670opendoar:2015-08-28T00:00Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)false |
dc.title.none.fl_str_mv |
Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study |
title |
Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study |
spellingShingle |
Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study Silva,Giovanni Faria Hepatitis C Advanced fibrosis Peginterferon Ribavirin |
title_short |
Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study |
title_full |
Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study |
title_fullStr |
Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study |
title_full_unstemmed |
Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study |
title_sort |
Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study |
author |
Silva,Giovanni Faria |
author_facet |
Silva,Giovanni Faria Villela-Nogueira,Cristiane A. Brandão Mello,Carlos Eduardo Soares,Elza Cotrim Coelho,Henrique Sergio M. Abrão Ferreira,Paulo Roberto Ruiz,Fernando José Goes |
author_role |
author |
author2 |
Villela-Nogueira,Cristiane A. Brandão Mello,Carlos Eduardo Soares,Elza Cotrim Coelho,Henrique Sergio M. Abrão Ferreira,Paulo Roberto Ruiz,Fernando José Goes |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Silva,Giovanni Faria Villela-Nogueira,Cristiane A. Brandão Mello,Carlos Eduardo Soares,Elza Cotrim Coelho,Henrique Sergio M. Abrão Ferreira,Paulo Roberto Ruiz,Fernando José Goes |
dc.subject.por.fl_str_mv |
Hepatitis C Advanced fibrosis Peginterferon Ribavirin |
topic |
Hepatitis C Advanced fibrosis Peginterferon Ribavirin |
description |
Background:Tolerance and response to antiviral HCV treatment is poor in advanced fibrosis. The aim of this study was to assess SVR rate and its predictive factors in HCV advanced fibrosis patients treated in real life with full dose PEG-IFN plus RBV and to evaluate the adverse events related to treatment.Methods:A multicentric, retrospective study was conducted at six university hospitals. METAVIR F3 and F4 HCV monoinfected patients who were treated with PEG-IFN and RBV had their data analyzed. A stepwise logistic regression analysis was performed to identify the variables independently related to SVR. Adverse events were recorded during treatment.Results:308 patients were included, 75% genotype 1 and 23% genotype 3. METAVIR F3 was present in 39% and F4 in 61% of patients. The median Child Pugh score for F4 patients was 5 (5–9). The global SVR rate was 34%, 11% were relapsers and 55% were nonresponders. SVR rates were similar between patients treated with PEG-IFN alfa 2a or alfa 2b (p = 0.24). SVR rates according to Child–Pugh score were 26% (Child A) and 18% (Child B). The independent factors related to SVR in F4 patients were genotype 3, RVR and fewer Child Pugh score points. Treatment interruption occurred in 31% patients and death occurred in 1.9%, all with liver cirrhosis.Conclusion:Treatment of HCV in patients with advanced fibrosis should not be postponed. However, a very careful evaluation of cirrhotic patients must be performed before treatment is indicated and careful monitoring is required during treatment. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702014000100048 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702014000100048 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1016/j.bjid.2013.05.007 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Brazilian Society of Infectious Diseases |
publisher.none.fl_str_mv |
Brazilian Society of Infectious Diseases |
dc.source.none.fl_str_mv |
Brazilian Journal of Infectious Diseases v.18 n.1 2014 reponame:Brazilian Journal of Infectious Diseases instname:Brazilian Society of Infectious Diseases (BSID) instacron:BSID |
instname_str |
Brazilian Society of Infectious Diseases (BSID) |
instacron_str |
BSID |
institution |
BSID |
reponame_str |
Brazilian Journal of Infectious Diseases |
collection |
Brazilian Journal of Infectious Diseases |
repository.name.fl_str_mv |
Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID) |
repository.mail.fl_str_mv |
bjid@bjid.org.br||lgoldani@ufrgs.br |
_version_ |
1754209242815922176 |